Roche Tecentriq FDA approval expands treatment for stage III dMMR colon cancer
FDA approval moves Tecentriq into adjuvant stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death risk.
Pharma & Biotech
Pharma & Biotech
Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment
Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.
Medical Devices & Diagnostics
What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Medical Devices & Diagnostics
Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care
Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.
Pharma & Biotech
Can Rznomics turn RZ-001 into a breakthrough therapy for hepatocellular carcinoma?
Rznomics reported interim RZ-001 liver cancer data at AACR 2026. Read why the efficacy and safety signals could matter for hepatocellular carcinoma.
Pharma & Biotech
Why Oncolytics Biotech’s new GOBLET cohort 4 data matters for third-line anal cancer immunotherapy strategies
Find out why Oncolytics Biotech’s latest GOBLET cohort 4 data could reshape immunotherapy strategies for third-line anal cancer.